Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

20.71 +0.20 (+0.98%)
Streaming Delayed Price Updated: 12:57 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 221,967
Open 20.44
Bid (Size) 20.68 (2)
Ask (Size) 20.73 (4)
Prev. Close 20.51
Today's Range 20.39 - 20.93
52wk Range 11.25 - 56.66
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
From Abraham, Fruchter & Twersky, LLP
Via GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-11.80%
-11.80%
1 Month
-19.88%
-19.88%
3 Month
-3.99%
-3.99%
6 Month
+66.35%
+66.35%
1 Year
-51.05%
-51.05%

More News

Read More
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics: Q4 Earnings Insights
Via Benzinga
11 Analysts Have This to Say About Akero Therapeutics
Via Benzinga
Akero Therapeutics: Q3 Earnings Insights
Via Benzinga
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
Via Investor's Business Daily
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.